Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma

BackgroundClinicopathologic (SARCULATOR) and transcriptomic (CINSARC) models are established prognostication tools in soft tissue sarcoma, but neither directly represent the sequence context of tumor genomic alterations. Evo2 is a genomic foundation model trained to learn the grammar of DNA/RNA sequences. We tested whether Evo2-derived features from tumor short variants, fusions, and rearrangements improve survival prognostication beyond clinicopathologic and transcriptomic risk models. MethodsWe analysed formalin-fixed, paraffin-embedded tumor material and clinical data from 102 patients with dedifferentiated liposarcoma (n = 25), high-grade leiomyosarcoma (n = 25), and undifferentiated pleomorphic sarcoma (n = 52). A separate TCGA-SARC cohort of comparable histologies (n = 129) served as external validation. Reconstructable alterations (short variants, fusions and rearrangements) were converted into sequence inputs, embedded with Evo2 and aggregated into patient-level genomic representations. Cox proportional hazards models incorporated genomic features alone (Evo2) or together with clinicopathologic (SARCULATOR) or transcriptomic (CINSARC) predictors across overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), relapse-free survival (RFS), and metastasis-free survival (MFS). Discrimination was assessed using Harrells concordance index (C-index). ResultsEvo2 features were generated from 174 study-cohort sequences and 7298 TCGA-SARC sequences. In the study cohort, adding Evo2 to SARCULATOR increased the reported C-index for OS from 0.620 to 0.770, PFS from 0.625 to 0.755, DFS from 0.612 to 0.714, and RFS from 0.633 to 0.771. In TCGA-SARC, SARCULATOR plus Evo2 increased the OS C-index from 0.595 to 0.716 and the MFS C-index from 0.548 to 0.667. Also in TCGA-SARC, adding Evo2 to CINSARC increased the OS C-index from 0.476 to 0.653 and the MFS C-index from 0.553 to 0.650. These are descriptive point-estimate comparisons. Moreover, in TCGA-SARC Evo2 alone outperformed SARCULATOR alone and CINSARC alone, supporting independent prognostic information within altered sequence-context representations. ConclusionsEvo2-derived genomic representations improved clinicopathologic and transcriptomic prognostication across sarcoma cohorts and survival endpoints. These findings support genomic foundation models as an independent and complementary layer for sarcoma risk stratification through direct modeling of altered tumor sequence biology. Confirmation of model transportability, calibration and clinical utility is required before clinical application. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/26363568v1_ufig1.gif" ALT="Figure 1"> View larger version (44K): org.highwire.dtl.DTLVardef@75ea85org.highwire.dtl.DTLVardef@177c306org.highwire.dtl.DTLVardef@1a4c4cborg.highwire.dtl.DTLVardef@741e88_HPS_FORMAT_FIGEXP M_FIG C_FIG Genomic sequence representations for sarcoma prognostication. Reconstructed short variants and study-cohort fusion proxies are processed with Evo2 and aggregated into patient-level genomic profiles for ridge-penalised Cox survival modelling. Genomic profiles are evaluated alone or with clinicopathologic SARCULATOR or transcriptomic CINSARC predictors; CINSARC is evaluated only in TCGA-SARC. The lower panel shows reported overall-survival Harrell C-index point estimates before and after adding Evo2 features. These descriptive comparisons do not establish statistical significance or clinical utility. {Delta} denotes the alternative-minus-reference difference in mean sequence log-likelihood. Embedding displacement denotes cosine distance between paired short-variant embeddings. FFPE, formalin-fixed, paraffin-embedded; TCGA-SARC, The Cancer Genome Atlas sarcoma cohort. Created using BioRender.